Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duratio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla, Haley Hedlin, Karen B. Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R. de Vries, Orlando Quintero, Kent Feng, Catherine Ley, Dean Winslow, Jennifer Newberry, Karlie Edwards, Colin Hislop, Ingrid Choong, Yvonne Maldonado, Jeffrey Glenn, Ami Bhatt, Catherine Blish, Taia Wang, Chaitan Khosla, Benjamin A. Pinsky, Manisha Desai, Julie Parsonnet, Upinder Singh
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/5fbb6d030f594c858730d7fccbf367da
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Here the authors report the results of randomized, single-blind, placebocontrolled trial on the effects of a asingle subcutaneous dose of Peginterferon Lambda-1a (Lambda) in 120 outpatients with mild to moderate COVID-19, showing that while treatment is well tolerated it does not shorten the duration of SARS-CoV-2 viral shedding nor improves symptoms.

Ejemplares similares